<DOC>
	<DOCNO>NCT02470052</DOCNO>
	<brief_summary>This multicenter , single-arm , open-label study design evaluate improvement lung function safety treatment OL-BF-001 severe emphysema . OL-BF-001 consist bronchial valve , deployment catheter , loader airway size kit . A bronchial valve small , umbrella-shaped , one-way valve place inside airway one lung . It use redirect air less healthy healthy part lung . This help reduce over-inflation may improve overall lung function quality life people live emphysema .</brief_summary>
	<brief_title>A Prospective Multicenter Clinical Study Evaluate Safety Effectiveness OL-BF-001 Severe Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>Subject treat maximum medical management（ pharmacological therapy nonpharmacological therapy ) 3 month screen test treatment conduct study period . Subject must severe dyspnea define mMRC ≥ 2 . Subject 's obstructive disease severe define follow postbronchodilator spirometry value : FEV1/FVC &lt; 70 % 20 % predict ≤ FEV1 &lt; 50 % predict Subject 's hyperinflation define : RV/TLC ≥ 40 % Subject severe emphysema high heterogeneity define : target lobe ≥ 50 % emphysema involvement clearly different ipsilateral lobe , judge visual assessment thoracic CT . Lung perfusion scan add assessment principle . The target lobe ipsilateral lobe separate intact fissure . An intact fissure estimate visually ≥ 90 % complete segmental vessel cross one lobe adjacent lobe . Subject must able demonstrate physical ability participate study perform 6minute walk distance ≥ 140 m. Subject abstain cigarette smoke 3 month screen testing , able continue abstain throughout study . Investigator confirm medical management conduct enough disease state stable without COPD exacerbation 6 week screen test . Subject able participate study , complete require followup visit , maintain consistent nutrition exercise habit study period . Subject provide informed consent willing able return study examination . Subject severe gas exchange abnormality either PaCO2 PaO2 define : PCO2 &gt; 50 mmHg , PO2 &lt; 50 mmHg room air Subject DLCO &lt; 20 % predict Subject BMI &lt; 15kg/m2 . Subject risk thromboembolism . ( Ddimer value use reference . ) Subject COPD exacerbation require hospitalization administration systemic steroid twice past 1 year prior screen test . Subject history pneumothorax twice past 1 year prior screen test . Subject large amount sputum production daily basis . Subject clinically apparent asthma . Subject giant bulla ( &gt; 1/3 volume either lung . If subject multiple bulla , sum judge whether &gt; 1/3 volume either lung . ) Patient pulmonary hypertension base upon clinical evaluation . Subject use oral steroid 10 mg/day prednisolone conversion . Subject comorbidities limit participation study , followup study period . Subject history thoracic surgery . Subject thoracic comorbidities ( lung nodule , infection ( e.g . Pulmonary tuberculosis ) , Interstitial pneumonia , etc . ) , anticipated require evaluation intervention 12 month study period . Subject strongly suspect pleural adhesion . Subject indicated Left ventricular ejection fraction ( LVEF ) ≤ 30 % within 6 month prior screen test . *Subject , severe cardiovascular disease past control currently , n't meet criterion . Subject judge ineligible due risk hemoptysis investigator . Subject demonstrate unwillingness inability complete screen and/or baseline test . Subject α1antitrypsin deficiency . Subject classify ASA Class great P4 comorbidities could significantly increase risk related bronchoscopy procedure . Subject latex allergy . Subject metallic allergy . Subject participate study investigational drug device within 30 day prior participation study , currently participate another clinical study . Following woman subject ineligible : Pregnant woman , lactate woman , potentially pregnant woman , woman wish become pregnant study period , woman use birth control properly study period . Subject consider ineligible due factor investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Endobronchial Valves</keyword>
	<keyword>Intrabronchial Valves</keyword>
	<keyword>Bronchial Valve</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
	<keyword>Bronchoscopic Lung Volume Reduction</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Pulmonary Emphysema</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Disease</keyword>
</DOC>